Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive HF
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): B Cell, Lymph Node
DISEASE(S): Lymphoma
SUBMITTER: Stefan Müller
LAB HEAD: Stefan Müller
PROVIDER: PXD027355 | Pride | 2022-02-17
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
20210630_GT_UP_EV_1.raw | Raw | |||
20210630_GT_UP_EV_2.raw | Raw | |||
20210630_GT_UP_EV_3.raw | Raw | |||
20210630_GT_UP_SENP6_1.raw | Raw | |||
20210630_GT_UP_SENP6_2.raw | Raw |
Items per page: 5 1 - 5 of 9 |
Schick Markus M Zhang Le L Maurer Sabine S Maurer Hans Carlo HC Isaakaidis Konstandina K Schneider Lara L Patra Upayan U Schunck Kathrin K Rohleder Elena E Hofstetter Julia J Baluapuri Apoorva A Scherger Anna Katharina AK Slotta-Huspenina Julia J Hettler Franziska F Weber Julia J Engleitner Thomas T Maresch Roman R Slawska Jolanta J Lewis Richard R Istvanffy Rouzanna R Habringer Stefan S Steiger Katja K Baiker Armin A Oostendorp Robert A J RAJ Miething Cornelius C Lenhof Hans-Peter HP Bassermann Florian F Chapuy Björn B Wirth Matthias M Wolf Elmar E Rad Roland R Müller Stefan S Keller Ulrich U
Nature communications 20220112 1
SUMOylation is a post-translational modification of proteins that regulates these proteins' localization, turnover or function. Aberrant SUMOylation is frequently found in cancers but its origin remains elusive. Using a genome-wide transposon mutagenesis screen in a MYC-driven B-cell lymphoma model, we here identify the SUMO isopeptidase (or deconjugase) SENP6 as a tumor suppressor that links unrestricted SUMOylation to tumor development and progression. Notably, SENP6 is recurrently deleted in ...[more]